PLRX Pliant Therapeutics Inc

Price (delayed)

$1.125

Market cap

$69.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

$72.04M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 14

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is ...

Highlights
The EPS has surged by 56% year-on-year and by 19% since the previous quarter
The net income has soared by 55% YoY and by 18% from the previous quarter
The company's quick ratio fell by 42% QoQ and by 25% YoY
The equity has contracted by 33% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of PLRX

PLRX stock price

How has the Pliant Therapeutics stock price performed over time
Intraday
-1.32%
1 week
5.14%
1 month
-2.6%
1 year
-22.95%
YTD
-7.79%
QTD
-1.32%

Financial performance

How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$97.48M
Net income
-$92.29M
Gross margin
N/A
Net margin
N/A
PLRX's operating income has soared by 56% year-on-year and by 18% since the previous quarter
The net income has soared by 55% YoY and by 18% from the previous quarter

Price vs fundamentals

How does PLRX's price correlate with its fundamentals

Growth

What is Pliant Therapeutics's growth rate over time

Valuation

What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 56% year-on-year and by 19% since the previous quarter
PLRX's price to book (P/B) is 72% lower than its 5-year quarterly average of 1.7 and 4% lower than its last 4 quarters average of 0.5
The equity has contracted by 33% YoY and by 11% from the previous quarter

Efficiency

How efficient is Pliant Therapeutics business performance
The ROE is up by 28% year-on-year and by 10% since the previous quarter
The company's return on invested capital rose by 28% YoY and by 10% QoQ
Pliant Therapeutics's return on assets has increased by 26% YoY and by 8% QoQ

Dividends

What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLRX.

Financial health

How did Pliant Therapeutics financials performed over time
The total liabilities has contracted by 46% YoY but it has grown by 15% from the previous quarter
The company's quick ratio fell by 42% QoQ and by 25% YoY
Pliant Therapeutics's debt is 80% lower than its equity
Pliant Therapeutics's debt has shrunk by 52% YoY
The equity has contracted by 33% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.